Literature DB >> 8122609

Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure.

E Sbarouni1, A Bradshaw, F Andreotti, E Tuddenham, C M Oakley, J G Cleland.   

Abstract

Thromboembolism is an important complication of heart failure. To test the hypothesis that heart failure may be associated with hemostatic dysfunction, we studied hemostatic function in 21 patients with stable chronic heart failure and related these measures to the severity of heart failure as assessed by clinical evaluation, neuroendocrine activation, radionuclide ventriculography, and cardiopulmonary exercise testing. Plasma and blood viscosity were elevated; all patients showed evidence of platelet activation, and many had elevated plasma concentrations of fibrinopeptide A, D-dimer, and von Willebrand factor. The plasma concentrations of these variables were poorly interrelated and related poorly to the severity of heart failure. Plasma concentrations of angiotensin II and endothelin were correlated, and the latter was also correlated with the plasma concentration of von Willebrand factor. Patients with chronic heart failure have hemostatic abnormalities that may predispose them to thromboembolic events and may be in part due to neuroendocrine activation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8122609     DOI: 10.1016/0002-8703(94)90670-x

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  25 in total

Review 1.  Is aspirin safe for patients with heart failure?

Authors:  J G Cleland; C J Bulpitt; R H Falk; I N Findlay; C M Oakley; G Murray; P A Poole-Wilson; C R Prentice; G C Sutton
Journal:  Br Heart J       Date:  1995-09

Review 2.  Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy.

Authors:  G Y Lip
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

Review 3.  The angiotensin-converting enzyme inhibitor and aspirin interaction in congestive heart failure: fear or reality?

Authors:  R Moskowitz
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

4.  Anticoagulation in Congestive Cardiomyopathy: Steps Toward Defining the Great Unknown.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 5.  Management strategies for a better outcome in unstable coronary artery disease.

Authors:  R W Campbell; L Wallentin; F W Verheugt; A G Turpie; A Maseri; W Klein; J G Cleland; C Bode; R Becker; J Anderson; M E Bertrand; C R Conti
Journal:  Clin Cardiol       Date:  1998-05       Impact factor: 2.882

6.  New methodologies to accurately assess circulating active transforming growth factor-β1 levels: implications for evaluating heart failure and the impact of left ventricular assist devices.

Authors:  Donna Mancini; Juan Monteagudo; Mayte Suárez-Fariñas; Jeffrey Bander; Rohan Varshney; Juana Gonzalez; Barry S Coller; Jasimuddin Ahamed
Journal:  Transl Res       Date:  2017-11-05       Impact factor: 7.012

7.  Clinically significant thrombosis in pediatric heart transplant recipients during their waiting period.

Authors:  Yuk M Law; Sumeet Sharma; Brian Feingold; Bret Fuller; William A Devine; Steven A Webber
Journal:  Pediatr Cardiol       Date:  2012-08-10       Impact factor: 1.655

8.  Thromboembolic risk in the patient with heart failure.

Authors:  Liviu Klein; John B O'connell
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

9.  N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy.

Authors:  Gerald Chi; James L Januzzi; Serge Korjian; Yazan Daaboul; Samuel Z Goldhaber; Adrian F Hernandez; Russell D Hull; Alex Gold; Alexander T Cohen; Robert A Harrington; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2017-11       Impact factor: 2.300

Review 10.  Psychobiology of depression/distress in congestive heart failure.

Authors:  Kaki M York; Mustafa Hassan; David S Sheps
Journal:  Heart Fail Rev       Date:  2008-03-27       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.